Literature DB >> 26782034

[Specific types of bladder cancer].

S Bertz1, A Hartmann2, R Knüchel-Clarke3, N T Gaisa4.   

Abstract

Bladder cancer shows rare variants and special subtypes with diverse prognostic importance and therefore may necessitate different therapeutic approaches. For pathologists it is important to histologically diagnose and specify such variants. Nested variants of urothelial carcinoma with inconspicuous, well-formed tumor cell nests present with an aggressive course. The plasmacytoid variant, which morphologically resembles plasma cells is associated with a shorter survival time and a high frequency of peritoneal metastasis. Micropapillary urothelial carcinoma with small papillary tumor cell islands within artificial tissue retraction spaces and frequent lymphovascular invasion also has a poor prognosis. Other important rare differential variants listed in the World Health Organization (WHO) classification are microcystic, lymphoepithelioma-like, sarcomatoid, giant cell and undifferentiated urothelial carcinomas. Additionally, there are three special types of bladder cancer: squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma of the bladder. These tumors are characterized by pure squamous cell or glandular differentiation and are sometimes less responsive to adjuvant (chemo)therapy. Small cell carcinoma of the bladder mimics the neuroendocrine features of its pulmonary counterpart, shows an aggressive course but is sensitive to (neo-)adjuvant chemotherapy. The morphology and histology of the most important variants and special types are discussed in this review.

Entities:  

Keywords:  Adenocarcinoma; Small cell neuroendocrine carcinoma; Squamous cell carcinoma; Urothelial carcinoma; Variants

Mesh:

Year:  2016        PMID: 26782034     DOI: 10.1007/s00292-015-0129-5

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  36 in total

1.  Plasmacytoid urothelial carcinoma of the bladder.

Authors:  Takurou Kohno; Masaya Kitamura; Hideyuki Akai; Minato Takaha; Kunimitsu Kawahara; Toshitugu Oka
Journal:  Int J Urol       Date:  2006-04       Impact factor: 3.369

2.  Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry.

Authors:  Antonio Lopez-Beltran; Maria J Requena; Jose Alvarez-Kindelan; Ana Quintero; Ana Blanca; Rodolfo Montironi
Journal:  J Clin Pathol       Date:  2006-08-01       Impact factor: 3.411

3.  Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation.

Authors:  Minghao Zhong; Wei Tian; Jian Zhuge; Xiaoyong Zheng; Tiangui Huang; Dongming Cai; David Zhang; Ximing J Yang; Pedram Argani; John T Fallon; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2015-01       Impact factor: 6.394

4.  Paraganglioma of the urinary bladder: can biologic potential be predicted?

Authors:  L Cheng; B C Leibovich; J C Cheville; D M Ramnani; T J Sebo; R M Neumann; A G Nascimento; H Zincke; D G Bostwick
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

5.  Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis.

Authors:  Farshid Dayyani; Bogdan A Czerniak; Kanishka Sircar; Mark F Munsell; Randall E Millikan; Colin P Dinney; Arlene O Siefker-Radtke
Journal:  J Urol       Date:  2012-11-15       Impact factor: 7.450

6.  Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma.

Authors:  Keith E Volmar; Theresa Y Chan; Angelo M De Marzo; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2003-09       Impact factor: 6.394

7.  Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.

Authors:  H Samaratunga; K Khoo
Journal:  Histopathology       Date:  2004-07       Impact factor: 5.087

8.  Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.

Authors:  J Tschui; E Vassella; N Bandi; U Baumgartner; V Genitsch; D Rotzer; R Seiler; G N Thalmann; A Fleischmann
Journal:  Virchows Arch       Date:  2015-03-26       Impact factor: 4.064

9.  Sensitivity of initial biopsy or transurethral resection of bladder tumor(s) for detecting histological variants on radical cystectomy.

Authors:  Peng Ge; Zi-Cheng Wang; Xi Yu; Jian Lin; Qun He
Journal:  BMC Urol       Date:  2015-05-30       Impact factor: 2.264

Review 10.  Primary choriocarcinoma of the urinary bladder--a case report.

Authors:  J H Cho; E Yu; K H Kim; I Lee
Journal:  J Korean Med Sci       Date:  1992-12       Impact factor: 2.153

View more
  6 in total

Review 1.  [Predictive biomarkers in bladder cancer].

Authors:  H Reis; T Szarvas
Journal:  Pathologe       Date:  2019-12       Impact factor: 1.011

Review 2.  [Predictive biomarkers in oncologic uropathology].

Authors:  H Reis; T Szarvas; V Grünwald
Journal:  Pathologe       Date:  2019-05       Impact factor: 1.011

3.  Bladder preservation versus radical cystectomy in transitional cell carcinoma and squamous cell carcinoma muscle invasive bladder cancer.

Authors:  Dalia O Mohamed; Mona M Sayed; Islam F Abdelkawi; Mahmoud H Elshoieby; Salah M Khallaf; Lamia M Khallaf; Doaa M Fouad
Journal:  Curr Urol       Date:  2021-03-29

Review 4.  Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?

Authors:  Yvonne Klaile; Katrin Schlack; Martin Boegemann; Julie Steinestel; Andres Jan Schrader; Laura-Maria Krabbe
Journal:  Transl Androl Urol       Date:  2016-10

Review 5.  Cisplatin for cancer therapy and overcoming chemoresistance.

Authors:  Ranmali Ranasinghe; Michael L Mathai; Anthony Zulli
Journal:  Heliyon       Date:  2022-09-14

Review 6.  Combination of histological and molecular data for improving outcome prediction in non-muscle invasive bladder cancer-narrative review.

Authors:  Radosław Piszczek; Wojciech Krajewski; Marco Moschini; Anna Kołodziej; Łukasz Nowak; Adrian Poterek; Romuald Zdrojowy
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.